SG10201607966UA - Artificial nucleic acid molecules comprising a 5'top utr - Google Patents

Artificial nucleic acid molecules comprising a 5'top utr

Info

Publication number
SG10201607966UA
SG10201607966UA SG10201607966UA SG10201607966UA SG10201607966UA SG 10201607966U A SG10201607966U A SG 10201607966UA SG 10201607966U A SG10201607966U A SG 10201607966UA SG 10201607966U A SG10201607966U A SG 10201607966UA SG 10201607966U A SG10201607966U A SG 10201607966UA
Authority
SG
Singapore
Prior art keywords
nucleic acid
acid molecules
artificial nucleic
top utr
utr
Prior art date
Application number
SG10201607966UA
Other languages
English (en)
Inventor
Andreas Thess
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of SG10201607966UA publication Critical patent/SG10201607966UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201607966UA 2012-03-27 2013-03-27 Artificial nucleic acid molecules comprising a 5'top utr SG10201607966UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2012001334 2012-03-27
EP2012002448 2012-06-08

Publications (1)

Publication Number Publication Date
SG10201607966UA true SG10201607966UA (en) 2016-11-29

Family

ID=48044723

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201607966UA SG10201607966UA (en) 2012-03-27 2013-03-27 Artificial nucleic acid molecules comprising a 5'top utr
SG11201405545XA SG11201405545XA (en) 2012-03-27 2013-03-27 Artificial nucleic acid molecules comprising a 5'top utr

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201405545XA SG11201405545XA (en) 2012-03-27 2013-03-27 Artificial nucleic acid molecules comprising a 5'top utr

Country Status (12)

Country Link
US (1) US10080809B2 (ru)
JP (1) JP6301906B2 (ru)
KR (1) KR20140139101A (ru)
CN (2) CN104321432B (ru)
AU (1) AU2013242405B2 (ru)
BR (1) BR112014023898A2 (ru)
CA (1) CA2866945C (ru)
ES (1) ES2660129T3 (ru)
MX (1) MX358706B (ru)
RU (1) RU2660565C2 (ru)
SG (2) SG10201607966UA (ru)
WO (1) WO2013143700A2 (ru)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
MX2019002345A (es) 2012-03-27 2022-08-24 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
MX358706B (es) 2012-03-27 2018-08-31 Curevac Ag Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
ES2739913T3 (es) 2013-02-22 2020-02-04 Curevac Ag Combinación de vacunación e inhibición de la ruta PD-1
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2702466T3 (es) 2013-08-21 2019-03-01 Curevac Ag Procedimiento para aumentar la expresión de proteínas codificadas por ARN
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
EP3035961A1 (en) 2013-08-21 2016-06-29 CureVac AG Rabies vaccine
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
EP3036330B1 (en) 2013-08-21 2018-09-12 CureVac AG Method for increasing expression of rna-encoded proteins
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
EP3586871A3 (en) 2013-08-21 2020-03-11 CureVac AG Respiratory syncytial virus (rsv) vaccine
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
KR102399799B1 (ko) * 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
EP3090053B1 (en) 2013-12-30 2018-11-21 CureVac AG Artificial nucleic acid molecules
EP3415629A1 (en) * 2013-12-30 2018-12-19 CureVac AG Artificial nucleic acid molecules
EP3590529A1 (en) 2014-03-12 2020-01-08 CureVac AG Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
AU2015273933B2 (en) 2014-06-10 2021-02-11 CureVac Manufacturing GmbH Methods and means for enhancing RNA production
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
DE202015009974U1 (de) 2014-12-12 2022-02-17 Curevac Ag Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
WO2016097065A1 (en) * 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
BR112017009835A2 (pt) * 2014-12-30 2017-12-26 Curevac Ag moléculas de ácido nucleico artificiais
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
WO2016165831A1 (en) 2015-04-17 2016-10-20 Curevac Ag Lyophilization of rna
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
SG11201708652YA (en) * 2015-05-15 2017-11-29 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
EP3916091A3 (en) 2015-05-20 2022-03-30 CureVac AG Dry powder composition comprising long-chain rna
US11608513B2 (en) 2015-05-29 2023-03-21 CureVac SE Method for adding cap structures to RNA using immobilized enzymes
PL3303583T3 (pl) 2015-05-29 2020-10-19 Curevac Real Estate Gmbh Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
AU2016285852B2 (en) 2015-06-29 2020-12-17 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3112469B1 (en) * 2015-06-30 2018-02-07 ethris GmbH Utrs increasing the translation efficiency of rna molecules
EP4239080A3 (en) 2015-07-01 2023-11-01 CureVac Manufacturing GmbH Method for analysis of an rna molecule
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
WO2017015630A2 (en) * 2015-07-23 2017-01-26 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3331555A1 (en) * 2015-08-05 2018-06-13 CureVac AG Epidermal mrna vaccine
ES2924739T3 (es) 2015-08-28 2022-10-10 Curevac Ag Moléculas de ácido nucleico artificiales
ES2969082T3 (es) 2015-09-17 2024-05-16 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
US20190225644A1 (en) 2015-10-16 2019-07-25 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
ES2914225T3 (es) 2015-10-16 2022-06-08 Modernatx Inc Análogos de cap de ARNm con enlace de fosfato modificado
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
EP3368507B1 (en) 2015-10-28 2022-12-07 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017081110A1 (en) 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
EP3383361B1 (en) * 2015-12-03 2021-08-11 DNA Essence GmbH Oligonucleotides in food, beverage, cosmetic and medicinal formulations
AU2016375021B2 (en) 2015-12-22 2022-02-03 CureVac SE Method for producing RNA molecule compositions
JP7114465B2 (ja) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド 薬剤の細胞内送達のための化合物および組成物
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
CN109104870B (zh) 2016-01-15 2021-10-15 丁恩雨 一种能够增强mRNA稳定性和可译性的通用核酸药物载体
US20210180106A1 (en) 2016-02-12 2021-06-17 Curevac Ag Method for analyzing rna
SG10201913630YA (en) * 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
US20190343942A1 (en) 2016-04-22 2019-11-14 Curevac Ag Rna encoding a tumor antigen
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP3452086A1 (en) 2016-05-04 2019-03-13 CureVac AG Influenza mrna vaccines
US11141474B2 (en) 2016-05-04 2021-10-12 Curevac Ag Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
RU2751001C2 (ru) 2016-06-09 2021-07-07 Кьюрвак Аг Гибридные носители для доставки нуклеиновых кислот
EP3468609A1 (en) 2016-06-09 2019-04-17 CureVac AG Cationic carriers for nucleic acid delivery
EP3468608A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
AU2017286606A1 (en) 2016-06-14 2018-12-13 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
SG10201913631TA (en) 2016-08-19 2020-03-30 Curevac Ag Rna for cancer therapy
MX2019004913A (es) 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
JP2020501545A (ja) * 2016-12-08 2020-01-23 キュアバック アーゲー 肝疾患の処置または予防のためのｒｎａ
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
US11464847B2 (en) * 2016-12-23 2022-10-11 Curevac Ag Lassa virus vaccine
CN108456669B (zh) * 2017-02-20 2023-08-08 上海凯赛生物技术股份有限公司 一种核糖体结合位点、重组表达质粒、转化子及其应用
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
FI3596041T3 (fi) 2017-03-15 2023-01-31 Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
US20200085944A1 (en) 2017-03-17 2020-03-19 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
CA3050616A1 (en) * 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP3615510B1 (en) 2017-04-28 2024-03-27 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20210198200A1 (en) 2017-06-14 2021-07-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2018237066A1 (en) * 2017-06-20 2018-12-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CODON OPTIMIZED HUMAN NPC1 GENES FOR THE TREATMENT OF C1-TYPE NIEMANN-PICK DISEASE AND ASSOCIATED STATES
CN111328287A (zh) 2017-07-04 2020-06-23 库瑞瓦格股份公司 新型核酸分子
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR PREPARING MODIFIED RNA
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2019077001A1 (en) * 2017-10-19 2019-04-25 Curevac Ag NEW ARTIFICIAL NUCLEIC ACID MOLECULES
SG11202003247RA (en) 2017-11-08 2020-05-28 Curevac Ag Rna sequence adaptation
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
KR20210006357A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
EP3773702A2 (en) 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
AU2019254591A1 (en) 2018-04-17 2020-09-10 CureVac SE Novel RSV RNA molecules and compositions for vaccination
US20210260178A1 (en) 2018-06-27 2021-08-26 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
EP3897702A2 (en) 2018-12-21 2021-10-27 CureVac AG Rna for malaria vaccines
JP2022523117A (ja) 2019-01-31 2022-04-21 モデルナティエックス インコーポレイテッド ボルテックスミキサならびにその関連する方法、システム、及び装置
SG11202108100PA (en) 2019-01-31 2021-08-30 Modernatx Inc Methods of preparing lipid nanoparticles
EP3920950A1 (en) 2019-02-08 2021-12-15 CureVac AG Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
CN109971786B (zh) * 2019-04-19 2022-09-23 上海市东方医院（同济大学附属东方医院） 核孔蛋白Nup54及其载体和重组腺病毒的用途
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
CN112190591B (zh) * 2019-07-08 2021-12-17 中国农业科学院兰州兽医研究所 核糖体蛋白rpl13抑制剂在制备抑制ires-依赖性翻译的病毒复制的药物中的应用
CN111041099B (zh) * 2019-07-22 2021-09-17 江苏医药职业学院 检测g蛋白偶联受体137b表达水平的试剂的应用和试剂盒
JP2022544412A (ja) 2019-08-14 2022-10-18 キュアバック アーゲー 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物
US20230392163A1 (en) 2019-10-17 2023-12-07 Ginkgo Bioworks Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
CN112980877A (zh) * 2019-12-12 2021-06-18 中国科学院大连化学物理研究所 一种提高外源基因表达效率的方法
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
KR20220144416A (ko) 2020-02-04 2022-10-26 큐어백 아게 코로나바이러스 백신
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
EP3865579A1 (en) * 2020-02-12 2021-08-18 Pantherna Therapeutics GmbH Recombinant nucleic acid construct and use thereof
IL294771A (en) * 2020-02-11 2022-09-01 Pantherna Therapeutics Gmbh Structure of recombinant nucleic acid and its use
CN111218458B (zh) * 2020-02-27 2020-11-20 珠海丽凡达生物技术有限公司 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法
CN111118018B (zh) * 2020-03-05 2021-06-01 泰州博莱得利生物科技有限公司 猫血清白蛋白重组蛋白及其在毕赤酵母中的表达方法
CN113874507A (zh) 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
BR112022020203A2 (pt) 2020-04-09 2022-11-22 Suzhou Abogen Biosciences Co Ltd Composição de nanopartículas lipídicas
JP2023530229A (ja) 2020-05-29 2023-07-14 キュアバック エスイー 核酸ベースの混合ワクチン
WO2022002040A1 (en) 2020-06-30 2022-01-06 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CA3170741A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
JP2023537887A (ja) 2020-08-20 2023-09-06 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
CN112662673B (zh) * 2021-01-08 2022-06-28 石河子大学 一种人klf7基因启动子及其构建方法与应用
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022200574A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4312988A2 (en) 2021-03-31 2024-02-07 CureVac SE Syringes containing pharmaceutical compositions comprising rna
CN113174427B (zh) * 2021-04-29 2023-02-28 遵义医科大学 基于DNA分子检测ERGIC3 mRNA的方法
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
CA3211623A1 (en) 2021-05-24 2022-12-01 Bo YING Lipid compounds and lipid nanoparticle compositions
CA3221100A1 (en) 2021-06-04 2022-12-08 Frank Derosa Assay for quantitative assessment of mrna capping efficiency
CN113801213B (zh) * 2021-06-23 2022-04-08 广东省农业科学院水稻研究所 一种拟禾本科根结线虫转录因子MgBTF3及其防治病害的应用
EP4377331A2 (en) 2021-07-30 2024-06-05 CureVac SE Mrnas for treatment or prophylaxis of liver diseases
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023044333A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
TW202325263A (zh) 2021-09-14 2023-07-01 美商雷納嘉德醫療管理公司 非環狀脂質及其使用方法
CN118043306A (zh) 2021-10-08 2024-05-14 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
KR20230083893A (ko) * 2021-12-03 2023-06-12 고려대학교 산학협력단 번역 효율이 향상된 5'-utr, 이를 포함하는 합성 핵산 분자 및 이를 포함하는 백신 또는 치료제 조성물
WO2023133525A1 (en) * 2022-01-07 2023-07-13 Precision Biosciences, Inc. Optimized polynucleotides for protein expression
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN114645029A (zh) * 2022-03-11 2022-06-21 上海交通大学 分离人工合成的MpgS蛋白质多肽和MpgP蛋白质多肽及其应用
WO2023196931A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN117517657B (zh) * 2024-01-08 2024-04-09 中国农业科学院北京畜牧兽医研究所 Lnx1基因或蛋白在调控禽类先天免疫应答反应中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
EP1005561A4 (en) 1997-03-21 2004-03-31 Enzo Therapeutics Inc A Fully VECTOR, VIRAL VECTORS AND PACKAGING CELL LINES TO THEIR REPRODUCTION
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
DE50214200D1 (de) 2001-06-05 2010-03-25 Curevac Gmbh Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
US8021875B2 (en) * 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
US7985553B2 (en) 2001-10-29 2011-07-26 Nathaniel Heintz Method for isolating cell type-specific mRNAs
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
GB0216414D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP2500437B1 (en) * 2003-01-21 2016-11-30 PTC Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
SI1685251T1 (sl) * 2003-10-10 2014-05-30 Powderject Vaccines, Inc. Konstrukti nukleinske kisline
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
TR201909609T4 (tr) * 2005-08-23 2019-07-22 Univ Pennsylvania Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
MX2010008468A (es) 2008-01-31 2010-08-30 Curevac Gmbh Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
US8968746B2 (en) 2010-07-30 2015-03-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
MX358706B (es) 2012-03-27 2018-08-31 Curevac Ag Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
MX2019002345A (es) 2012-03-27 2022-08-24 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
EP3498267A1 (en) 2012-05-25 2019-06-19 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
KR102399799B1 (ko) * 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자

Also Published As

Publication number Publication date
CN108929880A (zh) 2018-12-04
RU2014142881A (ru) 2016-05-20
US20150050302A1 (en) 2015-02-19
AU2013242405B2 (en) 2018-06-28
WO2013143700A3 (en) 2013-12-27
KR20140139101A (ko) 2014-12-04
JP2015517803A (ja) 2015-06-25
BR112014023898A2 (pt) 2017-07-11
CA2866945C (en) 2021-05-04
SG11201405545XA (en) 2014-11-27
AU2013242405A1 (en) 2014-09-25
CN104321432B (zh) 2018-08-10
CN104321432A (zh) 2015-01-28
RU2660565C2 (ru) 2018-07-06
WO2013143700A2 (en) 2013-10-03
ES2660129T3 (es) 2018-03-20
MX2014011625A (es) 2014-10-17
US10080809B2 (en) 2018-09-25
JP6301906B2 (ja) 2018-03-28
MX358706B (es) 2018-08-31
CA2866945A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
SG11201405545XA (en) Artificial nucleic acid molecules comprising a 5'top utr
SG10201607962RA (en) Artificial nucleic acid molecules
HK1210628A1 (en) Self-assembly of nucleic acid nanostructures
DK2922554T3 (en) Terminalt modificeret rna
SG11201503646TA (en) Esterification of 2,5-furan-dicarboxylic acid
EP2799548A4 (en) ANTISENSE NUCLEIC ACID
IL238410A0 (en) נגזרות טריסייקליק ת'יופן ממוזגות כמעכבי jak
IL231983A0 (en) Dna containing tricyclo-phosphorothioate
EP2612917A4 (en) ANTISENSE NUCLEIC ACID
EP2729182A4 (en) NUCLEIC COMPLEX
EP2647644A4 (en) RNA MODIFIED BY 2'-O
GB201204407D0 (en) Nucleic acid molecule
EP2691522A4 (en) FUNCTIONAL NUCLEIC ACID MOLECULE AND APPLICATIONS THEREOF
EP2799494A4 (en) SOLUTION OF POLYAMIC ACID
EP2915815A4 (en) NEW MODIFIED NUCLEIC ACID
ZA201206793B (en) Nucleic acid complexes
EP2700414A4 (en) SELF-GELATINABLE NUCLEIC ACID
EP2814960A4 (en) USE OF IDED NANOSTRUCTURES IN NUCLEIC ACID TECHNOLOGY
EP2682462A4 (en) (Nucleic acid) polysaccharide COMPLEX
HK1193407A1 (en) Pyrrolidine-3-ylacetic acid derivative -3-
EP2702999A4 (en) FUNCTIONAL NUCLEIC ACID TARGETING THE BRAIN AND USE THEREOF
EP2594592A4 (en) COMPLEX (NUCLEIC ACID) -POLYSACCHARIDE
GB201107286D0 (en) Nucleic acid preparation
GB201113678D0 (en) "Data-Tank"
GB201211286D0 (en) Novel biological factor